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The Wound Healing Society (WHS) is a professional soci-
ety of physicians, nurses, physical therapists, podiatrists,
and other wound care specialists, basic scientists, clinical
researchers, and industrial researchers dedicated to assur-
ing that every patient receives optimal wound care. Its
mission is to advance the science and practice of wound
healing. To that end, the following comprehensive, evi-
dence- and consensus-based guidelines were developed to
address The Prevention of Diabetic Ulcers. The guidelines
are presented in generic terms; the details of specific tests,
therapies, and procedures are at the discretion of an inter-
disciplinary team of health care professionals who estab-
lish, implement, and evaluate policies and procedures
directed at prevention of diabetic ulcers.
METHODS
PubMed, EMBASE, CINAHL, and the Cochrane Da-
tabase of Systematic Reviews were searched and reviewed
for evidence on arterial insufficiency ulcer prevention. In
addition, a search of health care databases for current ev-
idence-based guidelines addressing the prevention of dia-
betic ulcers was conducted using electronic and online
resources. The panel classified studies based on whether
the intervention being evaluated addressed diabetic ulcer
risk screening and assessment, diabetic ulcer prevention
plans of care (including interdisciplinary approaches), or
patient and caregiver education.
Evidence references for each standard are listed and
coded. The code abbreviations for the evidence citations
were as follows:
STAT Statistical analysis, meta-analysis, consensus
statement by commissioned panel of experts
RCT Randomized clinical trial
LIT REV Literature review
CLIN S Clinical case series
RETRO S Retrospective series review
EXP Experimental laboratory or animal study
TECH Technique or methodology description
PATH S Pathological series review
Classification of evidence
The strength of evidence supporting a guideline is listed
as Level I, Level II, or Level III, using the following
definitions:
 Level I:Meta-analysis of multiple RCTs or at least two
RCTs supporting the intervention in the guideline or
multiple laboratory or animal experiments with at least
two clinical series supporting the laboratory results.
 Level II: Less evidence than Level I, but at least
one RCT and at least two significant clinical series or
expert opinion papers with literature reviews support-
ing the intervention. Experimental evidence that is
quite convincing but without support by adequate
human experience.
 Level III: Suggestive data of proof-of-principle, but
lacking sufficient data such as meta-analysis, RCT or
multiple clinical series.
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GUIDELINES
Preamble: Patients with diabetes develop wounds as a re-
sult of neuropathy, peripheral vascular disease with is-
chemia, or both. In 2002, there were 19.3 million people
with diabetes mellitus, for a crude incidence of 9.3%. The
diagnosis of diabetes had been established in 6.5%, with
2.8% undiagnosed. There are now an estimated 20.8 mil-
lion people in the United States with diabetes. As many as
25% of these patients are at risk for ulceration during their
lifetimes. Preventing wounds may reduce the likelihood of
amputation. Establishing the proper diagnosis is impera-
tive, as is evaluation of the patient for the complications of
diabetes. Prevention of wounds in these patients involves
addressing these complications before ulceration.
1. Identifying Complications of Diabetes Leading to
Ulceration:
Guideline #1.1: In patients with diabetes, clinically signifi-
cant arterial disease should be ruled out by establishing
that pedal pulses are clearly palpable or that the ankle:bra-
chial index (ABI) is > 0.9. An ABI > 1.3 suggests non-
compressible arteries. In elderly patients or patients with
an ABI > 1.2, a normal Doppler derived wave form, a
toe:brachial index of > 0.7 or a transcutaneous oxygen
pressure of > 40mmHg may help to suggest an adequate
arterial flow. Color duplex ultrasound scanning provides
anatomic and physiologic data confirming atherosclerotic
occlusive disease.
Level of Evidence: I.
Principle: Diabetic ulcers can result from minor trauma in
patients with arterial insufficiency. Although clinical
history and physical examination can be suggestive of
ischemia of the lower extremity in a patient with diabetes,
a definitive diagnosis must be established.
Evidence:
1. Sahli D, Eliasson B, Svensson M, Blohme G, Eliasson
M, Samuelsson P, Ojbrandt K, Eriksson J. Assessment
of toe blood pressure is an effective screening method to
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2. Teodorescu V, Chen C, Morrissey N, Faries P, Marin
M, Hollier L. Detailed protocol of ischemia and the use
of noninvasive vascular laboratory testing in diabetic
foot ulcers. Am J Surg 2004; 187(5A): 75S–80S [LIT
REV].
3. Hirsch A, Criqui M, Treat-Jacobson D, Regensteiner J,
Creager M, Olin J, Krook S, Hunninghake D, Come-
rota A, Walsh M, McDermott M, Hiatt W. Peripheral
arterial disease detection, awareness, and treatment in
primary care. JAMA 2001; 286: 1317–24 [CLIN S].
4. Ascher E, Hingorani A, Markevich N, Yorkovich W,
Schutzer R, Hou A, Jacob T, Nahata S, Kallakuri S.
Role of duplex arteriography as the sole preoperative
imaging modality prior to lower extremity rev-
ascularization surgery in diabetic and renal patients.
Ann Vasc Surg 2004; 18: 433–9 [CLIN S].
5. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Crea-
ger MA, Halperin JL, Hiratzka LF, Murphy WRC,
Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley
JC, Taylor LM Jr, White CJ, White J, White RA. ACC/
AHA guidelines for the management of patients with
peripheral arterial disease (lower extremity, renal, mes-
enteric, and abdominal aortic): a collaborative report
from the american association for vascular surgery/so-
ciety for vascular surgery, society for cardiovascular
angiography and interventions, society of interventio-
nal radiology, society for vascular medicine and biolo-
gy, and the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines
(writing committee to develop guidelines for the man-
agement of patients with peripheral arterial disease).
American College of Cardiology Web Site. Available
at: http://www.acc.org/clinical/guidelines/pad/index.
pdf [STAT].
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Transcutaneous oxygen (TcPO2) estimates probability
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Guideline #1.2: The presence of significant neuropathy
that can render a patient at risk of foot ulceration can be
determined by testing with a 10 g (5.07) Semmes–Wein-
stein monofilament. Monofilament testing should be com-
bined with a clinical examination of the lower extremity
that focuses on the possible existence of foot deformity
and a symmetric sensory level below which there is reduced
sensation to pain, touch and vibration in both limbs.
Level of Evidence: II.
Principle: The most important causative factor of diabetic
foot ulcers is peripheral neuropathy. Neuropathy leads to
foot deformity with abnormal pressure on the foot, espe-
cially the plantar surface. Lack of protective sensation al-
lows ulceration in areas of high pressure. Autonomic
neuropathy may increase the likelihood of skin breakdown.
Evidence:
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monofilament examination for diabetic peripheral
neuropathy screening. J Diabetes Complications 2005;
19: 47–53 [CLIN S].
3. Foltz K, Fallat L, Schwartz S. Usefulness of a brief
assessment battery for early detection of Charcot foot
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foot: a comparison of standardized noninvasive test-
ing with routine practice at community diabetes clin-
ics. J Diabetes Complications 2001; 15: 63–8 [CLIN S].
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physiological predictors of foot lesions in patients
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Guideline #1.3: In patients with diabetes, laboratory values
such as hemoglobin A1c should be monitored.
Level of Evidence: II.
Principle:High glucose concentrations in the blood lead to
increased glycation of the hemoglobin molecules to form
hemoglobin A1C, which persists in circulation for up to 6
weeks. Therefore, measurement of plasma hemoglobin
A1C is the accepted standard for monitoring long-term
glucose control. Elevated hemoglobin A1C levels have
been correlated with a variety of comorbidities of diabe-
tes, such as cardiovascular and/or coronary heart disease,
retinopathy, neuropathy, and nephropathy/renal failure.
Elevated hemoglobin A1C has been shown to be a predic-
tive factor in the development of diabetic foot ulcers but
further research is still required.
Evidence:
1. Valeri D, Pozzilli P, Leslie D. Glucose control in diabe-
tes. Diabetes Metab Res Rev 2004; 20 (Suppl. 2): S1–8
[LIT REV].
2. Roberts SR, Hamedani B. Benefits and methods of
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3. Goldstein DE, Little RR, Lorenz RA, Malone JI, Na-
than DM, Peterson CM, American Diabetes Associa-
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2. Perform Foot Exam for Clinical Manifestations of Dia-
betes that Increase Risk of Ulceration:
Guideline #2.1: Patients with diabetes should have an an-
nual foot exam.
Level of Evidence: I.
Principle: Published guidelines uniformly recommend that
all diabetic patients have an annual foot examination that
includes assessment for anatomic deformities, skin breaks,
nail disorders, loss of protective sensation, diminished ar-
terial supply, and improper footwear. People with higher
risk for foot ulceration should have more frequent foot ex-
ams.
Evidence:
1. Singh N, Armstrong DG, Lipsky BA. Preventing foot
ulcers in patients with diabetes. JAMA 2005; 293:
217–28 [LIT REV].
2. Frykberg RG, Armstrong DG, Giurini JM, Edwards
A, Kravette M, Kravitz S, Ross C, Stavosky J, Stuck R,
Vanore J, American College of Foot and Ankle
Surgeons. Diabetic foot disorders: a clinical practice
guideline. J Foot Ankle Surg 2000; 39: S1–60 [STAT].
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cal Guidelines [book on CD-ROM]. Noordwijkerhout,
the Netherlands: International Working Group on the
Diabetic Foot, 1999 [STAT].
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7. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Po-
gach LM, American Diabetes Association. Preventive
foot care in people with diabetes. Diabetes Care 2004;
27 (Suppl. 1): S31–2 [STAT].
Guideline #2.2: Patients with diabetes should be examined
for callus formation.
Level of Evidence: III.
Principle:Callus formation, particularly with hemorrhage,
is a sign of impending skin breakdown and ulceration. Re-
moval of the callus results in lowered plantar pressures.
Evidence:
1. Brem H, Sheehan P, Rosenberg HJ, Schneider JS,
Boulton AJM. Evidence-based protocol for diabetic
foot ulcers. Plast Reconstr Surg 2006; 117 (7 Suppl.):
S193–209 [LIT REV].
2. Boulton AJ,Meneses P, Ennis WJ. Diabetic foot ulcers:
a framework for prevention and care. Wound Repair
Regen 1999; 7: 7–16 [LIT REV].
Guideline #2.3: Patients with diabetes should be examined
for fungal toenails.
Level of Evidence: III.
Principle: Onychomycosis, a fungal infection of the nails,
affects approximately one-third of patients with diabetes
and is the source of extensive morbidity. Fungal toenails
often harbor bacteria that can cause infection after injury
to the skin, often initiated by the sharp and brittle nails
themselves. Treatment options include oral antifungal
agents, topical therapy, and mechanical intervention.
Evidence:
1. Gupta AK, Konnikov N, MacDonald P, Rich P, Rod-
gers NW, Edmonds MW, McManus R, Summerbell
RC. Prevalence and epidemiology of toenail on-
ychomycosis: a multicentre survey. Br J Dermatol
1998; 139: 665–71 [CLIN S].
2. Bristow IR, Baran R. Topical and oral combination
therapy for toenail onychomycosis. J Am Podiatr Med
Assoc 2006; 96: 116–9 [LIT REV].
3. Drake LA, Patrick DL, Fleckman P, Andr J, Baran R,
Haneke E, Sapede C, Tosti A. The impact of on-
ychomycosis on quality of life: development of an in-
ternational onychomycosis-specific questionnaire to
measure patient quality of life. J Am Acad Dermatol
1999; 41: 189–96 [CLIN S].
4. Gupta AK, Humke S. The prevalence and management
of onychomycosis in diabetic patients. Eur J Dermatol
2000; 10: 379–84 [LIT REV].
5. Rich P. Onychomycosis and tinea pedis in patients
with diabetes. J Am Acad Dermatol 2000; 43: S130–4
[LIT REV].
6. Robbins JM. Treatment of onychomycosis in the dia-
betic patient population. J Diabetes Complications
2003; 17: 98–104 [LIT REV].
7. Bell-Syer SE, Hart R, Crawford F, Torgerson DJ, Tyrr-
ell W, Russell I. Oral treatments for fungal infections of
the skin and of the foot. Cochrane Database Syst Rev
2002; CD003584 [STAT].
8. Gupta AK, Einarson TR, Summerbell RC, Sherr NH.
An overview of topical antifungal therapy in dermato-
mycoses: a North American perspective. Drugs 1998;
55: 645–74 [LIT REV].
3. Surgery to Prevent Ulceration:
Guideline #3.1: Increased pressure on areas of the diabetic
foot results in callus formation, which can then lead to ul-
ceration. Removal of callus will reduce the likelihood of
ulceration.
Level of Evidence: I.
Principle: Paring callus will reduce pressure in areas at in-
creased risk for ulceration; therefore, all calluses should be
removed with few exceptions.
Evidence:
1. Murray HJ, Young MJ, Hollis S, Boulton AJ. The as-
sociation between callus formation, high pressures, and
neuropathy in diabetic ulceration.Diabet Med 1996; 13:
979–82 [CLIN S].
2. Duffin AC, Kidd R, Chan A, Donaghue KC. High
plantar pressure and callus in diabetic adolescents.
J Am Podiatr Med Assoc 2003; 93: 214–20 [CLIN S].
3. Slater RA, Hershkowitz I, Ramot Y, Buchs A, Rapo-
port MJ. Reduction in digital plantar pressure by debri-
dement and silicone orthosis. Diabetes Res Clin Pract
2006; 74: 263–6 [CLIN S].
4. Pataky Z, Golay A, Faravel L, DaSilva J, Makoundou
V, Peter-Riesch B, Assal JP. The impact of callosities
on the magnitude and duration of plantar pressure in
patients with diabetes mellitus. A callus may cause
18,600 kilograms of excess plantar pressure per day.
Diabetes Metab 2002; 28: 356–61 [CLIN S].
5. Young MJ, Cavanagh PR, Thomas G, Johnson MM,
Murray H, Boulton AJ. The effect of callus removal on
dynamic plantar foot pressures in diabetic patients.
Diabet Med 1992; 9: 55–7 [CLIN S].
6. Pitei DL, Foster A, Edmonds M. The effect of regular
callus removal on foot pressures. J Foot Ankle Surg
1999; 38: 251–5 [CLIN S].
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7. Brem H, Sheehan P, Rosenberg HJ, Schneider JS,
Boulton AJM. Evidence-based protocol for diabetic
foot ulcers. Plast Reconstr Surg 2006; 117 (7 Suppl.):
193S–209S [LIT REV].
Guideline #3.2:Achilles tendon lengthening decreases fore-
foot plantar pressure. This procedure may be recommend-
ed only for patients with history of repeated foot
ulceration in whom all other non-interventional care has
failed.
Level of Evidence: II.
Principle: Decreasing elevated forefoot plantar pressure is
associated with a decrease in risk of ulceration.
Evidence:
1. Maluf KS, Meuller MJ, Steube JJ, Engsberg JR, John-
son JE. Tendon Achilles lengthening for the treatment
of neuropathic ulcers cause of temporary reduction in
forefoot pressure associated with changes in plantar
flexor power rather than ankle motion during gait.
J Biomech 2004; 37: 897–906 [RCT].
2. Mueller MJ, Sinacore DR, Hastings MK, Strube MJ,
Johnson JE. Effect of Achilles tendon lengthening
on neuropathic plantar ulcers. A randomized clinical
trial. J Bone Joint Surg Am 2003; 85-A: 1436–45
[RCT].
3. Armstrong DG, Stacpoole-Shea S, Nguyen H, Hark-
less LB. Lengthening of the Achilles tendon in diabetic
patients who are at high risk for ulceration of the foot.
J Bone Joint Surg Am 1999; 81: 535–8 [CLIN S].
4. Hastins MK, Mueller MJ, Minacore DR, Salsich GB,
Engsberg JR, Johnson JE. Effects of a tendo-Achilles
lengthening procedure on muscle function and gait
characteristics in a patient with diabetes mellitus. J Or-
thop Sports Phys Ther 2000; 30: 85–90 [CLIN S].
5. Nishimoto GS, Attinger CE, Cooper PS. Lengthening
the Achilles tendon for the treatment of diabetic
plantar forefoot ulceration. Surg Clin North Am 2003;
83: 707–26 [LIT REV].
4. Protect the Diabetic Foot:
Guideline #4.1: Protective footwear should be pre-
scribed in any patient at risk for ulceration (significant
arterial insufficiency, significant neuropathy, or previous
amputation).
Level of Evidence: II.
Principle: Diabetic ulceration may result from an increase
in pressure in the diabetic foot because of foot deformity
and neuropathy. Offloading reduces the area of high pres-
sure. The incidence of ulceration in diabetic patients at risk
can be reduced by using protective footwear. Protective
footwear should be prescribed in any patient at risk for
amputation (such as significant arterial insufficiency, sig-
nificant neuropathy, previous amputation, previous ulcer
formation, pre-ulcerative callus, foot deformity, or evi-
dence of callus formation).
Evidence:
1. Janisse D. The Therapeutic Shoe Bill: medicare cover-
age for prescription footwear for diabetic patients. Foot
Ankle Int 2005; 26: 42–5 [CLIN S].
2. Pinzur M, Slovenkai M, Trepman E, Shields N. Diabe-
tes Committee of American Orthopaedic Foot and
Ankle Society. Guidelines for diabetic foot care: rec-
ommendations endorsed by the Diabetes Committee of
the American Orthopaedic Foot and Ankle Society.
Foot Ankle Int 2005; 26: 113–9 [LIT REV].
3. Reiber GE, Smith DG,Wallace C, Sullivan K, Hayes S,
Vath C, Maciejewski ML, Yu O, Heagerty PJ, LeMas-
ter J. Effect of therapeutic footwear on foot reulcer-
ation in patients with diabetes: a randomized controlled
trial. JAMA 2002; 287: 2552–8 [RCT].
4. Maciejewski ML, Reiber GE, Smith DG, Wallace C,
Hayes S, Boyko EJ. Effectiveness of diabetic therapeu-
tic footwear in preventing reulceration. Diabetes Care
2004; 27: 1774–82 [LIT REV].
5. Chantelau E, Kushner T, Spraul M. How effective is
cushioned therapeutic footwear in protecting diabetic
feet? A clinical study. Diabet Med 1990; 7: 355–59
[CLIN S].
6. Chantelau E, Haage P. An audit of cushioned diabetic
footwear: relation to patient compliance. Diabet Med
1994; 11: 114–6 [CLIN S].
7. Uccioli L, Faglia E, Monticone G, Favales F, Durola
L, Aldeghi A, Quarantiello A, Calia P, Menzinger G.
Manufactured shoes in the prevention of diabetic foot
ulcers. Diabetes Care 1995; 18: 1376–8 [RCT].
8. Donaghue VM, Sarnow MR, Giurini JM, Chrzan JS,
Habershaw GM, Veves A. Longitudinal in-shoe foot
pressure relief achieved by specially designed footwear
in high risk diabetic patients. Diabetes Res Clin Pract
1996; 31: 109–14 [CLIN S].
9. Sarnow MR, Veves A, Giurini JM, Rosenblum BI,
Chrzan JS, Habershaw GM. In-shoe foot pressure
measurements in diabetic patients with at risk feet
and healthy subjects. Diabetes Care 1994; 17: 1002–6
[CLIN S].
Guideline #4.2: Patients with healed diabetic ulcers should
use protective footwear to prevent recurrence.
Level of Evidence: II.
Principle: Diabetic ulcers of the lower extremity are a
chronic problem. Recurrence rates are 8–59%. Therefore,
long-term maintenance must be addressed even for healed
ulcers. Most treatments do not eliminate the underlying
increased pressure on the foot, so offloading is necessary
long term.
Evidence:
1. Maciejewski M, Reiber G, Smith D, Wallace C, Hayes
S, Boyko E. Effectiveness of diabetic therapeutic foot-
wear in preventing reulceration. Diabetes Care 2004;
27: 3024–5 [LIT REV].
2. Cavanagh PR. Therapeutic footwear for people with
diabetes. Diabetes Metab Res Rev 2004; 20 (Suppl. 1):
S51–5 [LIT REV].
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3. Boulton AJ. Pressure and the diabetic foot: clinical sci-
ence and off-loading techniques. Am J Surg 2004;
187(5A): 17S–24S [LIT REV].
4. Pinzur MS, Dart HC. Pedorthic management of
the diabetic foot. Foot Ankle Clin 2001; 612: 205–14
[LIT REV].
5. Lobmann R, Kayser R, Kasten G, Kasten U, Kluge K,
Neumann W, Lehnert H. Effects of preventive
footwear on foot pressures as determined by pedibaro-
graphy in diabetic patients: a prospective study. Diabet
Med 2001; 18: 314–9 [RCT].
6. Uccioli L, Faglia E, Monticone G, Favales F, Durola
L, Aldeghi A, Quarantiello A, Calia P, Menzinger G.
Manufactured shoes in the prevention of diabetic foot
ulcers. Diabetes Care 1995; 18: 1376–8 [RCT].
7. Colagiuri S, Marsden L, Naidu V, Taylor L. Use of
orthotic devices to correct planter callus in people with
diabetes. Diabetes Res Clin Pract 1995; 28: 29–34
[CLIN S].
8. Mueller MJ, Diamond JE, Sinacore DR, Delitto A,
Blair VP 3rd, Drury DA, Rose SJ. Total contact casting
in treatment of diabetic plantar ulcers. Controlled clin-
ical trial. Diabetes Care 1989; 12: 384–8 [CLIN S].
9. Reiber GE, Smith DG, Wallace C, et al. Effect of ther-
apeutic footwear on foot reulceration in patients with
diabetes: a randomized controlled trial. JAMA 2002;
287: 2552–8 [RCT].
5. Good Foot Care:
Guideline #5.1: Good foot care and daily inspection of the
feet will reduce the incidence of diabetic ulceration. It may
be necessary for a family member or caregiver to help with
these tasks.
Level of Evidence: II.
Principle: Good foot care, including proper bathing and
nail trimming, and the use of proper footwear, will reduce
ulceration in diabetic feet.
Evidence:
1. Pinzur M, Slovenkai M, Trepman E, Shields N: Diabe-
tes Committee of American Orthopaedic Foot and An-
kle Society. Guidelines for diabetic foot care:
recommendations endorsed by the Diabetes Commit-
tee of the American Orthopaedic Foot and Ankle Soci-
ety. Foot Ankle Int 2005; 26: 113–9 [LIT REV].
2. Jeffcoate W, Price P, Harding K: International Working
Group on Wound Healing and Treatments for People
with Diabetic Foot Ulcers. Wound healing and treat-
ments for people with diabetic foot ulcers. Diabetes Me-
tab Res Rev 2004; 20 (Suppl 1): S78–89 [LIT REV].
3. PinzurM. The diabetic foot.Compr Ther 2002; 28: 232–
7 [LIT REV].
4. Suico JG, Marriott DJ, Vinicor F, Litzelman DK. Be-
haviors predicting foot lesions in patients with non-in-
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